Interesting ImagesEffect of Leflunomide Use on 68Ga-DOTATATE Biodistribution in a Case With Neuroendocrine TumorTatar, Gamze MD∗; Beyhan, Ediz MD†; Arslan, Esra MD†; Ergül, Nurhan MD†; Çermik, Tevfik Fikret MD† Author Information From the Departments of ∗Nuclear Medicine, Istanbul Bagcilar Training and Research Hospital †Clinic of Nuclear Medicine, Istanbul Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. Received for publication May 18, 2022; revision accepted November 4, 2022. Conflicts of interest and sources of funding: none declared. Correspondence to: Gamze Tatar, MD, Department of Nuclear Medicine, Istanbul Bagcilar Training and Research Hospital, University of Health Sciences, Dr. Sadik Ahmet Cad. 34200 Bagcilar, Istanbul, Turkey. E-mail: [email protected]. Clinical Nuclear Medicine 48(2):p e71-e73, February 2023. | DOI: 10.1097/RLU.0000000000004517 Buy Metrics Abstract A 58-year-old man who underwent surgery for a well-differentiated neuroendocrine tumor of pancreatic origin was evaluated with 68Ga-DOTATATE PET/CT imaging in the follow-up period. After PET/CT findings consistent with disease remission, the patient was started on leflunomide treatment with the diagnosis of rheumatoid arthritis. The patient received leflunomide for 6 months. Then, 68Ga-DOTATATE PET/CT scan was repeated to evaluate the primary disease outcome. Besides the disease remission, we also observed alterations in DOTATATE uptakes of some tissues and organs. In this case, we present the changes in 68Ga-DOTATATE PET/CT scan findings after leflunomide use. Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.